With 15 acquisition offers this year alone, Valeant Pharmaceuticals International Inc. chief executive J. Michael Pearson looks like a wheeler-dealer in a hurry.
But his latest bet, a $2.6-billion cash bid for U.S.-based Medicis Pharmaceutical Corp., is all about slowing down the effects of time. It’s a gambit to grab a larger share of the anti-aging and dermatology products market. The belief? That spending money to look younger and healthier will only increase in the years ahead.
Click here to read the article.